| Oct 22 |
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
|
| Oct 3 |
Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now
|
| Sep 30 |
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
|
| Sep 26 |
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
|
| Sep 18 |
IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?
|
| Sep 14 |
Allogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer Stock
|
| Sep 6 |
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
|
| Aug 27 |
Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
|
| Aug 10 |
Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript
|
| Aug 9 |
Allogene Therapeutics Second Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.53 loss in 2Q 2023)
|
